Selective inhibitory action of Biginelli-type dihydropyrimidines on depolarization-induced arterial smooth muscle contraction

Abstract

Compounds A and, particularly, D are potent calcium channel blockers in vitro, with a better selectivity in inhibiting depolarization-induced arterial smooth muscle contraction than nifedipine.

Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents

“…A few compounds with dihydropyrimidine structure have been described as displaying antihypertensive activity through blocking of Ca 2+ channels. [36][37][38][39] However, they have neither been designed nor evaluated simultaneously as antimitotic agents.…”

Synthesis and Evaluation of Triazolyl Dihydropyrimidines as Potential Anticancer Agents

“…It has been reported for various biological activities like antibacterial (Sangaraiah, et al, 2012), antifungal (Rami, et al, 2013), antiviral (Hockova, et al, 2003, Breault, et al, 2003, anticancer (Sosnicki, et al, 2014), antihypertensive (Chikhale, et al, 2009) with calcium channel blocking and dihydrofolate reductase inhibition. In addition, these compounds emerged as potential α 1a -adrenergic antagonists (Schneider, et al, 2003), vasodilators (Cernecka, et al, 2012), antiatherosclerotic (Dobrusin, et al, 2001), antidiabetic (Lauro, et al, 2010), antiplatelet aggregation (Bruno, et al, 2001) and neuropeptide antagonists (Chikhale, et al, 2009). The chemistry of Pyrimidines has been extensively studied, since the Pyrimidine is a symmetrical molecule about the line passing through C 2 and C 5 , the N 1 and N 3 positions are equivalent and so are C 4 and C 6 .…”